Orchestra BioMed reported FY 2025 net loss of USD 52.7 million, compared with FY 2024 net loss of USD 61.02 million. Total revenue rose more than 12x to USD 33.48 million, driven by partnership revenue of USD 32.87 million following the termination and right of first refusal agreement with Terumo, including USD 10 million for the ROFR and USD 7.4 million tied to a premium above the fair market value of Series A preferred stock. Research and development expense increased 36% to USD 58.19 million as the company advanced its BACKBEAT hypertension study and initiated the Virtue SAB pivotal trial, while selling, general and administrative expense rose 12% to USD 26.91 million. Net cash used in operating activities was USD 48.96 million, and cash and cash equivalents plus marketable securities totaled USD 106.5 million at year-end. The company said it expects existing liquidity plus committed receipts, including USD 20 million from a Medtronic loan agreement and USD 15 million from Ligand, to fund operations into the fourth quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-026754), on March 12, 2026, and is solely responsible for the information contained therein.